The course of established ankylosing spondylitis and the effects of sulphasalazth over 3 years

J. Kirwan*, A. Edwards, B. Huitfeldt, P. Thompson, H. Currey

*Corresponding author for this work

    Research output: Contribution to journalArticle (Academic Journal)peer-review

    73 Citations (Scopus)

    Abstract

    A 3-year placebo-controlled trial of sulphasalazine (SASP) in 89 patients with established AS (including radiological sacroiliitis) showed a reduced frequency of peripheral arthritis in the treated group but did not show any definite benefit in the maintenance of spinal mobility. Adverse effects causing treatment withdrawal occurred in five placebo-treated patients and eight SASP-treated patients, but 22 patients preferred to stop taking daily medication of unproven benefit for the full3 years. The natural history of established AS suggested two groups of patients: the majority with principally spinal symptoms and infrequent peripheral arthritis or iritis, and a minority who tend to have recurrent extra-spinal problems.

    Original languageEnglish
    Pages (from-to)729-733
    Number of pages5
    JournalRheumatology
    Volume32
    Issue number8
    DOIs
    Publication statusPublished - 1 Aug 1993

    Keywords

    • Natural history
    • Peripheral arthritis
    • Spinal mobility

    Fingerprint Dive into the research topics of 'The course of established ankylosing spondylitis and the effects of sulphasalazth over 3 years'. Together they form a unique fingerprint.

    Cite this